The Dublin drugmaker on Tuesday said the planned $40 billion sale of its generics business to Teva Pharmaceutical Industries will close next month and that it will use $8 billion of the money to pay down company debt. Since the U.S. government torpedoed the merger, a deal that would have relocated Pfizer's legal domicile to Ireland to reduce Pfizer's taxes, investors have speculated Allergan might use the Teva proceeds for sizeable new deals.
The rest is here:
Allergan profit beats estimates, share buybacks planned